Deputy Chief Physician, Department of Thoracic Oncology II, Beijing Cancer Hospital; Doctor of Clinical Medicine, Peking University Areas of Expertise: Specializes in the medical treatment of common and rare types of lung cancer, malignant pleural mesothelioma, thymic carcinoma, and other thoracic malignancies. Proficient in comprehensive diagnosis and treatment involving targeted therapy, immunotherapy, and novel drugs. Has participated in or led multiple domestic and international clinical studies and translational research on new oncology drugs. Professional Affiliations: Secretary of the Lung Cancer Subcommittee, Beijing Association for Cancer Prevention and Treatment; Member of the Adverse Drug Reactions Subcommittee, Beijing Association for Cancer Prevention and Treatment; Member of the Chinese Society of Clinical Oncology; Member of the Chinese Anti-Cancer Association. Academic Publications: Co-editor of *Comprehensive Geriatric Lung Cancer Treatment*. Principal investigator of research projects funded by the Wu Jieping Medical Foundation and the Beijing Association for Cancer Prevention and Treatment. Published multiple articles, including: "Prognostic factor analysis of patients with small cell lung cancer: Real-world data from 988 patients," *Thoracic Cancer*, 2021 Jun;12(12); "Clinical outcomes of atezolizumab in combination with etoposide/platinum for treatment of extensive-stage small-cell lung cancer: A real-world, multicenter, retrospective, controlled study in China," *Chinese Journal of Cancer Research*, 2022 Aug 30;34(4).